Literature DB >> 9611670

Effects of ketamine on thought disorder, working memory, and semantic memory in healthy volunteers.

C M Adler1, T E Goldberg, A K Malhotra, D Pickar, A Breier.   

Abstract

BACKGROUND: The N-methyl-D-aspartate receptor antagonist, ketamine, produces a clinical syndrome of thought disorder, perceptual distortion, and cognitive impairment.
METHODS: We have administered ketamine to healthy volunteers to characterize the formal thought disorder and specific memory dysfunction associated with ketamine. Ten healthy volunteers underwent a double-blind, placebo-controlled, ketamine infusion (0.12 mg/kg bolus and 0.65 mg/kg/hour). Thought disorder was evaluated with the Scale for the Assessment of Thought, Language and Communication. Cognitive testing involved working and semantic memory tasks.
RESULTS: Ketamine produced a formal thought disorder, as well as impairments in working and semantic memory. The degree of ketamine-induced thought disorder significantly correlated with ketamine-induced decreases in working memory and did not correlate with ketamine-induced impairments in semantic memory.
CONCLUSIONS: This study characterizes the formal thought disorder associated with ketamine and may suggest that ketamine-induced deficits in working memory are associated with ketamine-induced thought disorder.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9611670     DOI: 10.1016/s0006-3223(97)00556-8

Source DB:  PubMed          Journal:  Biol Psychiatry        ISSN: 0006-3223            Impact factor:   13.382


  79 in total

Review 1.  N-methyl-d-aspartate (NMDA) receptor dysfunction or dysregulation: the final common pathway on the road to schizophrenia?

Authors:  Joshua T Kantrowitz; Daniel C Javitt
Journal:  Brain Res Bull       Date:  2010-04-24       Impact factor: 4.077

Review 2.  Schizophrenia and tobacco smoking comorbidity: nAChR agonists in the treatment of schizophrenia-associated cognitive deficits.

Authors:  Manoranjan S D'Souza; Athina Markou
Journal:  Neuropharmacology       Date:  2011-02-01       Impact factor: 5.250

3.  Oxycodone lengthens reproductions of suprasecond time intervals in human research volunteers.

Authors:  Cynthia M Gooch; Brian C Rakitin; Ziva D Cooper; Sandra D Comer; Peter D Balsam
Journal:  Behav Pharmacol       Date:  2011-08       Impact factor: 2.293

Review 4.  Region-specific changes in gamma and beta2 rhythms in NMDA receptor dysfunction models of schizophrenia.

Authors:  Anita K Roopun; Mark O Cunningham; Claudia Racca; Kai Alter; Roger D Traub; Miles A Whittington
Journal:  Schizophr Bull       Date:  2008-06-09       Impact factor: 9.306

5.  Emotion recognition deficits as predictors of transition in individuals at clinical high risk for schizophrenia: a neurodevelopmental perspective.

Authors:  C M Corcoran; J G Keilp; J Kayser; C Klim; P D Butler; G E Bruder; R C Gur; D C Javitt
Journal:  Psychol Med       Date:  2015-06-04       Impact factor: 7.723

Review 6.  Ketamine for chronic pain: risks and benefits.

Authors:  Marieke Niesters; Christian Martini; Albert Dahan
Journal:  Br J Clin Pharmacol       Date:  2014-02       Impact factor: 4.335

7.  Ketamine impairs multiple cognitive domains in rhesus monkeys.

Authors:  Michael A Taffe; Sophia A Davis; Tannia Gutierrez; Lisa H Gold
Journal:  Drug Alcohol Depend       Date:  2002-10-01       Impact factor: 4.492

8.  Effects of combined 5-HT2A and cannabinoid receptor modulation on a schizophrenia-related prepulse inhibition deficit in mice.

Authors:  Adriana M Marques; Michele V Macena; Aline R Cardoso; Camila S O Hammes; Fernanda M L Pinheiro; Newton G Castro; Gilda A Neves
Journal:  Psychopharmacology (Berl)       Date:  2020-02-24       Impact factor: 4.530

9.  Pharmacogenetic associations of the type-3 metabotropic glutamate receptor (GRM3) gene with working memory and clinical symptom response to antipsychotics in first-episode schizophrenia.

Authors:  Jeffrey R Bishop; James L Reilly; Margret S H Harris; Shitalben R Patel; Rick Kittles; Judith A Badner; Konasale M Prasad; Vishwajit L Nimgaonkar; Matcheri S Keshavan; John A Sweeney
Journal:  Psychopharmacology (Berl)       Date:  2014-08-07       Impact factor: 4.530

10.  NMDA receptor hypofunction leads to generalized and persistent aberrant gamma oscillations independent of hyperlocomotion and the state of consciousness.

Authors:  Tahir Hakami; Nigel C Jones; Elena A Tolmacheva; Julien Gaudias; Joseph Chaumont; Michael Salzberg; Terence J O'Brien; Didier Pinault
Journal:  PLoS One       Date:  2009-08-25       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.